Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Baclofen Clear all
Recruiting Not applicable Interventional

Intrathecal Baclofen and Pediatric Dystonia

NCT06606574
View directory record Official record
Conditions
Dystonic Cerebral Palsy
Interventions
Titration protocol
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Not applicable Interventional

Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia

NCT00004431
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
L-baclofen
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ALK29-002: A Study of Baclofen Formulations in Healthy Adults

NCT00802035
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Baclofen IR, Baclofen ER
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

NCT01325220
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
arbaclofen, Placebo
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 11 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Long Beach, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Baclofen Effects in Cigarette Smokers

NCT01821560
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Baclofen, placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Baclofen on Marijuana Withdrawal and Relapse

NCT00373295
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Baclofen, Marijuana, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain

NCT03068897
View directory record Official record
Conditions
Low Back Pain
Interventions
Metaxalone, Tizanidine, Baclofen, Ibuprofen 600 mg, Educational intervention
Drug · Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS

NCT03319732
View directory record Official record
Conditions
Multiple Sclerosis, Spasticity, Muscle
Interventions
Arbaclofen
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Bioequivalence Comparison of Baclofen and Chlorzoxazone Administered Individually or Concurrently

NCT05257447
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Baclofen 20 mg Tablet, Chlorzoxazone 500 mg Tablet, Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

NCT00139789
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Kemstro
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Timeline
2005
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Tolerability of Baclofen for Alcohol Dependence

NCT00877734
View directory record Official record
Conditions
Alcohol Dependence
Interventions
baclofen, placebo, BRENDA counseling
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional Results available

Baclofen to Reduce Alcohol Use in Veterans With HCV

NCT01008280
View directory record Official record
Conditions
Hepatitis C, Alcohol Use Disorders
Interventions
baclofen, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Long Beach, California • San Diego, California • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Early Phase 1 Interventional

Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression

NCT07560878
View directory record Official record
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Traditional Lecture Versus Procedural Video

NCT05495282
View directory record Official record
Conditions
Educational Problems
Interventions
Microvideo
Other
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Early Phase 1 Interventional Results available

Neurophysiological and Acute Pharmacological Studies in FXS Patients

NCT02998151
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Acamprosate, Lovastatin, Minocycline, Placebo, Baclofen
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
15 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Vaginal Baclofen Suppositories in Chronic Pelvic Pain

NCT05968937
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome
Interventions
20 mg baclofen vaginal suppository daily per vagina, Placebo
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Not yet recruiting Not applicable Interventional

Measuring Pelvic Floor Muscle Fitness Before and After Treatment

NCT07605598
View directory record Official record
Conditions
Myofacial Pain, Pelvic Pain, Myofascial Pelvic Pain, Chronic Pelvic Pain
Interventions
Near Infrared Imaging
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 4 Interventional

Vanderbilt University Spasticity Management Program Evaluation Plan

NCT00179114
View directory record Official record
Conditions
Spasticity
Interventions
Botulinum Toxin Type A, Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2007 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated Phase 3 Interventional Results available

Preventing Alcohol Withdrawal Syndrome With Oral Baclofen

NCT02052440
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Completed No phase listed Observational Results available

Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery

NCT01117090
View directory record Official record
Conditions
Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
Interventions
Not listed
Lead sponsor
MedtronicNeuro
Industry
Eligibility
12 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of High Dose Baclofen for Alcohol Dependence

NCT01980706
View directory record Official record
Conditions
Alcoholism
Interventions
Baclofen, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 1, 2026, 2:52 PM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

NCT04271332
View directory record Official record
Conditions
16P11.2 Deletion Syndrome
Interventions
Arbaclofen, Placebo oral tablet
Drug
Lead sponsor
Clinical Research Associates, LLC
Other
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

NCT01743651
View directory record Official record
Conditions
Spasticity, Multiple Sclerosis
Interventions
arbaclofen, baclofen, Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Cullman, Alabama • Long Beach, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 1, 2026, 2:52 PM EDT